Gregory Raskin, MD, is the Executive Director of the Office of Technology Development (OTD) at Memorial Sloan-Kettering Cancer Center. He leads a team of 14 professionals who work within OTD’s four units: Technology Management and Commercialization, Contracts, New Ventures and Business Development, and Operations and Finance.
Prior to joining Memorial Sloan-Kettering, in 2012, Greg was a Vice President at AllianceBernstein LP, where he led healthcare and life sciences investing for the firm’s $200 million venture capital fund. His previous experience includes serving as a biotech analyst at Baker Brothers Investments, and as a management consultant at McKinsey & Company, where he worked mainly with pharmaceutical and biotech companies.
Greg received a medical degree in 1998 and a BA degree in molecular biophysics and biochemistry in 1994, both from Yale University. During 1998-99, Greg was a resident physician in the internal medicine department of New York University Medical Center. He is a licensed physician in New York State.